• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Intrarosa (prasterone vaginal insert)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Intrarosa (prasterone vaginal insert)

  • Profile

Profile

Contact Information

Contact: Millicent Pharma
Website: https://us.intrarosa.com/

Currently Enrolling Trials

    Show More

    General Information

    Intrarosa (prasterone) is an inactive endogenous steroid and is converted into active androgens and/or estrogens. The mechanism of action of Intrarosa in postmenopausal women with vulvar and vaginal atrophy is not fully established.

    Intrarosa is specifically indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. 

    Intrarosa is supplied as a vaginal insert. Administer one Intrarosa vaginal insert once daily at bedtime, using the provided applicator.

    Mechanism of Action

    Intrarosa (prasterone) is an inactive endogenous steroid and is converted into active androgens and/or estrogens. The mechanism of action of Intrarosa in postmenopausal women with vulvar and vaginal atrophy is not fully established.

    Side Effects

    Adverse effects associated with the use of Intrarosa may include, but are not limited to, the following:

    • vaginal discharge
    • abnormal Pap smear

    Clinical Trial Results

    The FDA approval of Intrarosa for moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause was based on two primary 12-week placebo-controlled efficacy trials. The trials enrolled 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA. The women were randomly assigned to receive Intrarosa or a placebo vaginal insert. All subjects were assessed for improvement from Baseline to Week 12 for four co-primary efficacy endpoints: most bothersome moderate to severe symptom of dyspareunia, the percentage of vaginal superficial cells, the percentage of parabasal cells, and vaginal pH. Intrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse. 

    Approval Date: 2016-11-01
    Company Name: Millicent Pharma
    Back to Listings

    Upcoming Events

    • 07Jun

      Developing World-Class SOPs: Optimizing Quality and Compliance

    • 08Jun

      Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • MAGI East 2023

      MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

    • Complexity-360x240.png

      Phase 3 Trials Significantly Rising in Complexity, Says CSDD

    • Quality Level Scale

      Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

    • DE&I

      Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing